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ABSTRACT: A series of organometallic ruthenium(II)
complexes containing iminophosphorane ligands have been
synthesized and characterized. Cationic compounds with
chloride as counterion are soluble in water (70−100 mg/
mL). Most compounds (especially highly water-soluble 2) are
more cytotoxic to a number of human cancer cell lines than
cisplatin. Initial mechanistic studies indicate that the cell death
type for these compounds is mainly through canonical or
caspase-dependent apoptosis, nondependent on p53, and that
the compounds do not interact with DNA or inhibit protease
cathepsin B. In vivo experiments of 2 on MDA-MB-231
xenografts in NOD.CB17-Prkdc SCID/J mice showed an impressive tumor reduction (shrinkage) of 56% after 28 days of
treatment (14 doses of 5 mg/kg every other day) with low systemic toxicity. Pharmacokinetic studies showed a quick absorption
of 2 in plasma with preferential accumulation in the breast tumor tissues when compared to kidney and liver, which may explain
its high eﬃcacy in vivo.

■

INTRODUCTION

platinum-based drugs, ruthenium compounds can exchange N
and O-donor molecules with the added advantage of the
possibility of forming octahedral complexes (of interest in
reactions with DNA). Lastly, ruthenium derivatives probably
use transferrin6,7 to accumulate into tumors due to the
similarities with iron.
From all the ruthenium compounds reported as potential
anticancer agents, there are four main groups (Chart 1) that
have been studied in more detail and display important

In the search for metal-based chemotherapeutics with improved
properties with respect to platinum-based drugs used in the
clinic, ruthenium compounds have emerged as promising
candidates.1−5 Ruthenium complexes have certain characteristics that make them attractive as potential chemotherapeutics
for diﬀerent diseases.4,5 Ruthenium compounds can easily
access three diﬀerent oxidation states (II, III, and possibly IV)
in biological ﬂuids. Ruthenium(III) compounds could potentially behave as pro-drugs as they can be reduced to
ruthenium(II) derivatives in solid tumor masses where the
low content in oxygen may act as a reducing environment. As
© 2014 American Chemical Society
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Chart 1. Selected Ruthenium(III) and (II) Compounds with Important Antitumor and/or Antimetastatic Properties (Refs
4−21,30−32 and Refs Therein)

Chart 2. Selected Iminophosphorane (IM) d8 Transition Metal Complexes with Signiﬁcant Anticancer Properties Prepared in
Our Group44−49

antitumor and/or antimetastatic activities and low toxicity.1−8
The ﬁrst group corresponds to ruthenium(III) coordination
complexes with two compounds currently undergoing clinical
trials, NAMI-A4,9 (phase I/II), developed by Sava et al., and the
compound KP1019 and its analogue containing Na +
KP1339,4,10 developed by Keppler and co-workers (phase I/
II). A number of organometallic ruthenium(II) compounds
with arene ligands (piano-stool structure) have also been
described as promising candidates.4,6,11−19 Two relevant
examples from the groups of Sadler (RM175) and Dyson
(RAPTA-T), which have undergone advanced preclinical
studies, are depicted in Chart 1. Another important group of
ruthenium compounds in the preclinical stage is that of
cyclometalated compounds based on pincer C,N ligands (RDC
family).4,11,20,21 The recent strategy to bind a drug of wellknown therapeutic value (such as curcumin, ketoconazole,
clotrimazole, hydroxyﬂavones, hydroxyquinolinones, letrozole,
indolobenzazepins, or aspirin) to ruthenium centers has
rendered a number of complexes with improved properties
with respect to the parent organic drugs for cancer, e.g., refs

22−29. In this context, ruthenium compounds resembling
staurosporine (like DW1/2 in Chart 1) developed by Meggers
and co-workers are relevant examples of potential chemotherapeutics targeting protein kinases.4,11,30−32
A simple search on the SciFinder database on the concepts
“ruthenium anticancer” since 2010 shows over 800 hits. There
are now examples of multinuclear ruthenium compounds,33,34
of ruthenium derivatives which can be activated by light,35 that
are thermoresponsive,36 that can be obtained by a combinatorial approach,37 as well as ruthenium compounds that can be
delivered to tumor sites more eﬃciently by binding to
polymers,38 nanocarriers,39,40 peptides,41,42 or transport
proteins43 to mention a few advances in this ﬁeld. However,
there is still a need to ﬁnd the ultimate target(s) for these
ruthenium compounds as well as to get a better knowledge on
the detailed molecular mechanism of action in order to develop
more powerful and selective chemotherapeutics.4 In addition,
more in vivo data is needed to make more reliable predictions
of structure−biological activity correlations.8,18
9996
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Scheme 1. Preparation of Cationic Ruthenium(II) Compounds Containing IM Ligands

phorane ligands has been described by Urriolabeitia and coworkers.50 We have employed here p-cymene as the arene
group coordinated to the ruthenium centers. Thus, compounds
1−4 can be easily obtained in high yields by the addition of
diﬀerent IM ligands previously described46−49,51 to [(η6-pcymene)Ru(μ-Cl)Cl]252 (Scheme 1). 4 is an example of a new
heterometallic ruthenium complex containing a ferrocene
fragment.
Ruthenium(II) complexes with cyclometalated IM (pincer
C,N−) ligands have been prepared by transmetalation with
organomercury derivatives.50 However, the nature of the IM
ligand played a crucial role and compounds with semistabilized
IM ligands containing carbonyl groups like (2-C6H4)Ph2PNCO-Ph could not be obtained due to steric reasons.50
We aimed to prepare cycloruthenated compounds in which
the aryl group of the imino fragment is coordinated to the
metal center (exo derivatives) as opposed to an aryl group of
the phosphine fragment (endo derivatives) in order to be able
to incorporate diﬀerent phosphines into the ﬁnal molecule to
tune electronic/steric properties of the resulting complexes. We
followed the strategy for the preparation of Hg(Ph3PN-CO2-C6H4)Cl.53 The C−H activation at the N-CO-Ph fragments
takes place at a manganese center, and by transmetalation of
the resulting cyclometalated iminophosphorane manganese
compounds to HgCl2, the organomercury derivatives with PPh3
[Hg(Ph3PN-CO-2-C6H4)Cl]53 or water-soluble phosphine
PTA [Hg(PTAN-CO-2-C6H4)Cl] (7) are obtained in high
yields. Transmetalation reactions of [Hg(Ph3PN-CO-2C6H4)Cl]53 and 7 with [(η6-p-cymene)Ru(μ-Cl)Cl]2 aﬀord
new cyclometalated compounds [(η6-p-cymene)Ru(IM-k-

We have reported that nontoxic iminophosphorane or
iminophosphane (IM) compounds (R3PN-R′, IM) are useful
precursors for the preparation of coordination (N,N−) or
cyclometalated (C,N−) complexes of d8 metals (Au(III),
Pd(II), and Pt(II)) mono- or heterometallic (selected
compounds a−g in Chart 2).
These IM metal complexes display high cytotoxicity in vitro
(low micromolar to nanomolar) against a variety of human
cancer cell lines with diﬀerent degrees of selectivity.44−49
Organo-gold(III) complexes containing iminophosphorane
ligands (e.g., a) exert cell death with pathways involving
mitochondrial production of ROS.44,45 We have studied the
interaction of the IM metal compounds with (pBR322) DNA
and HSA.47−49 We have conﬁrmed that some compounds (f, g)
inhibit PARP-1 proteins.48 In most cases (including Pd(II) and
Pt(II) derivatives), we have demonstrated that DNA is not the
target for these compounds and that the complexes are highly
active against cisplatin-resistant cancer cell lines (such as Jurkat
sh-Bak, MCF7, or A2780cisR) pointing to a mode of action
diﬀerent from that of cisplatin.45−49
In this context, we aimed to explore the potential of IM
complexes containing metals other than d8 transition metals
(Au(III), Pd(II), and Pt(II)) as anticancer agents. We report
here on the preparation and preliminary biochemical and
biological studies (in vitro and in vivo eﬀects on human cancer
cells and xenografts) of organometallic ruthenium(II) compounds containing diﬀerent iminophosphorane ligands.

■

RESULTS AND DISCUSSION
1. Synthesis and Characterization. The synthesis of
ruthenium(II) piano-stool complexes containing iminophos9997
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Scheme 2. Preparation of the New Cycloruthenated Compounds 8 and 9 Containing IM Ligands

C,N)Cl] (IM = Ph3PN-CO-2-C6H4 8; PTAN-CO-2-C6H4
9) in high yields (Scheme 2).
All the compounds are obtained as air stable solids in
moderate to high yields. Their structures have been proposed
on the basis of microanalytical, spectroscopic (IR and NMR),
conductivity, and MS data. Some of the compounds are slightly
hygroscopic. As previously proposed by Urriolabeitia and coworkers,50 the IM ligand in compounds 1 and 2 is bonded as a
chelate giving a fac-Cl,N,O arrangement, while in compounds 3
and 4, the arrangement is fac-Cl,N,N. This can be clearly
inferred from the IR data. There is a strong absorption at 1531
cm−1 due to νCO stretch for 1 and 2 shifted to lower
frequencies with respect to that of the free ligand at 1598 cm−1.
For 3 and 4, the signal that can be assigned to νPN stretch is
shifted to lower frequency than that of the free ligands (see
Experimental Section). As previously described for compounds
containing benzene and some IM ligands,50 the 31P{1H} NMR
signals for 1 and 2 resemble that of the free ligand, whereas for
3 and 4, the signals are strongly shifted to low ﬁeld with respect
to the free ligands, indicating iminic N-bonding. In addition,
the ortho protons of the quinoline (H2) and pyridine (H6) in
the 1H NMR spectra for 3 and pyridine (H6) for 4 are shifted
downﬁeld, supporting the idea of N-coordination. Compound 4
shows ﬂuxional behavior at room temperature (giving rise to
broad signals in the 1H NMR spectrum in the area of the pcymene and Cp rings), and its variable temperature NMR
spectra are collected in the Supporting Information.
The structure of 1 has been determined by an X-ray analysis,
and it is very similar to that of previously reported50 [(η6C6H6)Ru(k-N,O-Ph3PN-CO-2-N-C5H4)]PF6 with very close
distances and angles. The molecular structure for the cation of
1 is depicted in Figure 1.
The analysis conﬁrms the piano-stool structure around the
ruthenium center as well as the coordination of the IM ligand
through the N and O atoms. Ru−C distances are on average
slightly longer, and the O(1)−Ru(1)−N(1) and N(1)−
Ru(1)−Cl(1) angles slightly smaller for 1 than for the
compound with (η6-C6H6)50 as expected.
Compounds 8 and 9 are cycloruthenated neutral species with
the IM ligand in an exo disposition [(η6-p-cymene)Ru(IM-kC,N)] (IM = Ph3PN-CO-2-C6H4 8, PTAN-CO-2-C6H4
9). Their 1H NMR spectra show signals due to η6-arene as well
as the C6H4P units. In addition, the 13C{1H} NMR spectrum
shows six well-resolved peaks due to the C6H4P unit. The
signals in the 31P{1H} NMR spectra are strongly shifted
downﬁeld with respect of those for the free ligand as reported
before for endo cycloruthenated species.50
The cationic compounds with chloride as counterion (2, 3,
and 4) are highly soluble in water (70−100 mg/mL). The
cycloruthenated derivative 9 with a water-soluble phosphine

Figure 1. Molecular structure of the cation of compound 1. Selected
distances (Å) and angles (deg): Ru(1)−O(1) 2.110(3), Ru(1)−N(1)
2.095(4), Ru(1)−C(10) 2.153(5), Ru(1)−C(6) 2.154(5), Ru(1)−
C(7) 2.171(5), Ru(1)−C(9) 2.187(5), Ru(1)−C(11) 2.191(5),
Ru(1)−C(8) 2.204(5), Ru(1)−Cl(1) 2.3775(14), O(1)−C(16)
1.266(6), C(1)−N(2) 1.337(7), C(1)−C(2) 1.385(8), N(2)−P(1)
1.619(5); N(1)−Ru(1)−O(1) 76.68(14), O(1)−Ru(1)−Cl(1)
83.61(10), N(1)−Ru(1)−Cl(1) 83.13(12).

PTA (9) is much less soluble in water (1 mg/mL 9). 1 and
cyclorutenated 8 and 9 are soluble in micromolar concentrations in 1:99 DMSO:H2O mixtures. All the complexes but 9
are stable for weeks in DMSO-d6 solution (see spectra and
stability table in the Supporting Information). The stability of
the water-soluble complexes was studied by 31P{1H} and 1H
NMR spectroscopy in D2O. The spectrum in D2O for
compound [(η 6 -p-cymene)Ru{Cp-P(Ph 2 )N-CH 2 -2NC5H4}Fe(Cp)}]Cl (4) does not change for over 3 days,
but after that time the compound precipitates. The 31P{1H}
NMR spectrum in D2O for 3 (δ = 37.73 ppm) shows an
additional signal (δ = 38.34 ppm) that may be assigned to a
hydrolyzed species of the type [(η6-p-cymene)Ru(Ph3PN-8C9H6N)(OH2)]2+. The integration of these signals is ca. 45:55,
and the spectrum does not change much over time (days). In
the case of compound 2 (δ in D2O 26.33 ppm), a signal
(attributable to [(η6-p-cymene)Ru(Ph3PN-CO-2-N-C5H4)(OH2)]+ is also visible in D2O (δ = 26.65 ppm) along with
another signal (δ = 43.79 ppm) which may correspond to the
cyclometalated species [(η 6 -p-cymene)Ru(IM-k-C,NC6H4(PPh2N-CO-2-N-C5H4)Cl] or [(η6-p-cymene)Ru(IMk-C,N-C6H4(PPh2N-CO-2-N-C5H4)(OH2)]+ and grows
overtime. The 1H NMR spectrum of 2 in D2O after 5 days
shows (in addition to those of compound 2) signals due to new
species containing η6-arene as well as the C6H4P unit indicating
the cyclometalation of the PPh3 ring. In addition, the 13C{1H}
9998
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Table 1. IC50 (μM) of Metal Complexes 1−4, 8−9, [(η6-p-cymene)Ru(μ-Cl)Cl]2a, and Cisplatin in Human Cell Linesb,c
1
2
3
4
8
9
cisplatin

Jurkat

A549

±
±
±
±
±
±
±

9.9 ± 1.9
9.5 ± 2.1
43.3 ± 8.0
>125
29.9 ± 5.8
>125
114.2 ± 9.1

1.1
0.78
0.9
9.3
2.39
17.7
10.8

0.14
0.08
0.32
0.07
0.27
7.5
1.2

DU-145

MiaPaca2

MDA-MB-231

±
±
±
±
±
±
±

2.4 ± 0.18
2.9 ± 0.8
7.0 ± 0.4
>125
8.2 ± 0.98
54.5 ± 16
76.5 ± 7.4

4.91 ± 2.7
2.61 ± 1.2
16.2 ± 0.9
>125
7.1 ± 0.11
75.4 ± 9.8
131.2 ± 18

1.89
1.55
6.6
148
14.2
125.5
112.5

0.64
0.21
0.85
33
4.2
28
33

HEK-293T
2.8
2.8
2.2
114.5
4.1
141.9
69.0

±
±
±
±
±
±
±

0.2
0.2
1.1
14.8
0.06
13.1
6.7

IC50 for [(η6-p-cymene)Ru(μ-Cl)Cl]2 >125 μM in all cell lines. bData are expressed as mean ± SD (n = 4). cAll compounds were dissolved in 1% of
DMSO and diluted with water before addition to cell culture medium for a 24 h incubation period. Cisplatin was dissolved in H2O.

a

than cisplatin for the pancreas MiaPaca2 and triple negative
breast MDA-MB-231 cell lines.
To assess the compounds’ selectivity for cancerous cells with
respect to normal cell lines, they were also screened for their
antiproliferative eﬀects on the nontumorigenic human embryonic kidney cells HEK293T. In most cases, the cytotoxicity is
comparable for the cancerous and HEK293T cells. All
compounds are more toxic to leukemia than to HEK293T
cell lines (2−8 times) and compounds 1, 2, and 9 are more
toxic to the prostate DU-145 cancer cell line than to HEK cell
lines. In addition, 9 is more toxic to the pancreas MiaPaca2
cancer cell line and to the breast cancer MDA-MB-231 cell line
than to HEK293T although the IC50s for those cell lines are
higher than other compounds in the table.
Importantly, as HEK cell lines are immortalized cells that can
display a higher sensitivity to chemicals, we measured the eﬀect
of compound 2 on human renal proximal tubular cells (RPTC).
Renal proximal tubular cells in primary culture have been
described as an in vitro model to study nephrotoxicity.54 The
IC50 value (XTT assay 24 h, see Experimental Section) for 2 in
this cell line was 13.84 ± 1.46 μM (the value obtained for
cisplatin as control was 46.42 ± 2.46 μM, similar to a values
previously reported55 for 24h in rabbit RPTC). Thus, 2 is more
toxic to all the cancer cell lines studied than to the “healthy”
human renal cell line and markedly more toxic to the leukemia
Jurkat-T (17.7-fold), prostate DU145 (9-fold), triple negative
breast cancer MDA-MB-231 (5.3-fold), and pancreas MiaPaca
(4.7-fold) cancer cell lines.
2, with an IC50 of 2.64 μM, is 30 times more cytotoxic in
MDA-MB-231 breast cancer cell lines than compound RM175
(Chart 1) with an IC50 of 62 μM under the same conditions
(MTT, 24 h incubation). The toxicity of RM175 in HBL100
human epithelial cell lines (IC50 = 54 μM) was similar to that in
breast cancer cell lines.14
2.2. Mechanism of Cell Death. The mechanism of cell death
induced by 2 and 3 was explored in Jurkat cells. Nuclei
morphology after 24 h incubation with 1 μM solution of 2 or 3
was analyzed by Hoechst staining. Typical apoptotic features,
chromatin condensation and fragmentation, were detected as
shown in Figure 2.
We then analyzed other apoptotic parameters such as
phosphatidylserine exposure and mitochondrial membrane
potential dissipation, using ﬂuorescent probes as indicated in
the Experimental Section. Dose−response experiments (Figure
3, right panel) conﬁrmed that 2 is more cytotoxic than 3, as also
indicated by MTT assays. Time-course experiments indicated
that 2 induced apoptosis in around 80% of cells after 8 h
treatment (Figure 3, left panel). Trypan blue staining conﬁrmed
that cell death was through apoptosis, with very low secondary
necrotic cells at 6 h (data not shown). Phosphatidylserine

NMR spectrum shows most of the six peaks due to this C6H4P
unit. The doublet that can be assigned to the CO peak for
these new cyclometalated species appears at 176.06 ppm
(versus 178.08 ppm for 2), and it is closer to the chemical shift
observed when CO is not coordinated to the ruthenium
center (like in the case of the free ligand which displays a
doublet at 175.34). The MS spectra of 2 in H2O overtime
shows a peak at m/z = 617 with a pattern ﬁtting that of cationic
species [(η6-p-cymene)Ru(IM-k-C,N-C6H4(PPh2N-CO-2N-C5H4)]+ (see Supporting Information). We have reported
cyclometalation processes at RT in DMSO of arylgroups from
PPh3 in IM coordination complexes of Pd and Pt with the
Ph3PN-8-C9H6N IM ligand.49 The half-life for 2 (14.5 mM)
in D2O is 2.5 days (although the process slows down for more
concentrated samples). The cyclometalation process for 2
proceeds faster in a 100 mM NaCl solution in D2O (half-life ca.
10 h for a concentration of 2 of 14.5 mM) and by increasing the
temperature (60% after 1 h at 80 °C). However, as it will be
explained in section 2, the biological activity of compound 2 is
very fast (in 8 h it induces 80% of apoptosis on Jurkat cells),
and thus we believe that the biological activity observed comes
mainly from coordination compound 2 or its hydrolysis
product.
2. Biological Activity in Vitro. 2.1. Antiproliferative
Studies in Vitro. The antiproliferative properties of the new
ruthenium complexes 1−4, 8, and 9 and of the starting material
[(η6-p-cymene)Ru(μ-Cl)Cl]2 were assayed by monitoring their
ability to inhibit cell growth using the MTT assay (see
Experimental Section). Cytotoxic activity of the compounds
was determined as described in the Experimental Section in
several human cancer cell lines: leukemia Jurkat-T, lung A549,
prostate DU-145, pancreas MiaPaca2, and triple negative breast
MDA-MB-231, in comparison to cisplatin. The results are
summarized in Table 1. The starting material [(η6-p-cymene)Ru(μ-Cl)Cl]2 is poorly cytotoxic in all tested cell lines (IC50
>125 μM). The IM ligands coordinated to the ruthenium
centers are known to be poorly cytotoxic (IC50 in diﬀerent cell
lines >100−500 μM).46−49
Compounds with coordinated IM ligands 1−3 and with the
IM-PPh3 cyclometalated ligand 8 were considerably more
cytotoxic than cisplatin in all the cell lines studied. Compounds
1 and 2 (same cation) display almost identical IC50 values, but
2 is soluble in H2O. The ruthenium compound based on an
iminophosphorane ligand containing a ferrocenyl phosphine
Fe−Ru 4 was less cytotoxic than cisplatin. The bimetallic
compounds Fe−Au and Fe−Pd also showed higher IC50 values
when compared to trimetallic derivatives or compounds with
diﬀerent IM ligands. The cycloruthenated compound containing a water-soluble IM ligand (IM-PTA) was more cytotoxic
9999
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Figure 2. Nuclei morphology after treatment of Jurkat cells with
compounds 2 and 3.

exposure and loss of transmembrane mitochondrial potential
occurred in the same percentage of cells, although at longer
incubation periods, there was an apparent decrease in the
percentage of AnnexinV positive cells that was in fact due to
cell disintegration. Apoptosis induction was slower for 3, with
the percentage of both AnnexinV+ and ΔΨmlow cells gradually
increasing during the 24 h period of the experiments (Figure 3,
left panel).
Proteins of the Bcl-2 family are key regulators of apoptosis,
and the levels of some members are modiﬁed in early phases of
the process. Thus, we analyzed the eﬀect of 2 in the levels of
two antiapoptotic proteins of the Bcl-2 family (Bcl-XL and Mcl1) and three proapoptotic members (Bim, Puma, and Noxa) in
Jurkat cells (Supporting Information, Figure 31). Jurkat cells
express very low levels of the other antiapoptotic member (Bcl2). The main changes observed after treatment with 2 were a
high increase in the levels of the propapoptotic proteins Noxa,
Puma (isoform b), and Bim (isoform β). Also a slight decrease
in the levels of the antiapoptotic members Bcl-XL and Mcl-1
was observed in cells treated with 2. The proapoptotic proteins
are damage sensors that induce the activation of Bax and Bak
and mitochondrial permeabilization to release cytochrome c,
the key event in the intrinsic pathway of apoptosis.56
Taken together, these results point to a classical apoptosis
mechanism of cell death. This was conﬁrmed by the ﬁnding
that the cytotoxicity of both compounds was caspase-dependent (Figure 4). The general caspase inhibitor z-VAD-fmk
completely abrogated PS exposure but it only partially reduced
ΔΨm loss (from 80% to 30% for 2 and from 40% to 20% for 3).
Because ΔΨm disruption was not completely inhibited by zVAD-fmk, we hypothesize that 2 and 3 could activate caspaseindependent pathways acting on mitochondria. To determine
whether caspase inhibition prevented or just delayed cell death,
we performed experiments in which cells were treated with 2 or
3 for 24 h in the presence of z-VAD-fmk and then washed and
further cultured in fresh medium for 24 h (Figure 5). PS

Figure 4. Eﬀect of the general caspase inhibitor z-VAD-fmk in
apoptotic features induced by 2 and 3.

Figure 5. Analysis of long-term protection by z-VAD-fmk.

exposure was analyzed after the ﬁrst 24 h in the presence of
compound+z-VAD-fmk and 24 h after washing. Only around
20% of cells were AnnexinV+ after 24 h incubation with 2+zVAD-fmk and 24 h in fresh medium, while 70% of cells treated
with 2 alone were apoptotic at the end of the experiments.
Thus, these results indicate that in the case of compound 2,

Figure 3. Dose−response quantiﬁcation of PS exposure (A) and time-course analysis of PS exposure and ΔΨm loss (B) caused by 2 and 3 in Jurkat
cells.
10000
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DNA−DNA and DNA−protein cross-links.59 Organometallic
piano-stool ruthenium(II) compounds based on biphenyl rings
RM175 interact strongly with DNA binding to guanines and by
intercalation.60,61 Organometallic ruthenium(II) RAPTA derivatives, characterized by the presence of water-soluble TPA
phosphine, exhibit pH-dependent DNA damage: at the pH
typical of hypoxic tumor cells DNA was damaged, whereas at
the pH characteristic of healthy cells little or no damage was
detected.62,63 Cycloruthenated compounds based on pincer
C,N ligands (RDC family) displayed a much weaker interaction
with plasmid (pBR322) DNA when compared to cisplatin.64,65
Complexes of the type [Ru(Cp)(2,2-bipy)(PR3)][CF3SO3]
have shown no observable interaction with DNA.66
In this context, we evaluated the eﬀect of DNA interactions
that could, to some extent, contribute to the observed
cytotoxicity of compounds 1−4, 8, and 9 and the apoptotic
behavior of compounds 2 and 3. We followed the interaction
with Calf Thymus DNA (CT DNA) by circular dichroism
(CD), and with plasmid pBR322 DNA by electrophoresis in
agarose gel. The CD spectral technique is very sensitive to
diagnose alterations on the secondary structure of DNA that
result from DNA−drug interactions. A typical CD spectrum of
CT DNA shows a positive band with a maximum at 275 nm
due to base stacking, and a negative band with a minimum at
248 nm due to helipticity, characteristic of the B conformation.67 Therefore, changes in the CD signals can be assigned to
corresponding changes in DNA secondary structure. In
addition, it is known that simple groove binding or electrostatic
interaction of small molecules cause little or no alteration in any
of the CD bands when compared to major perturbations
induced by covalent binding or intercalation.
CD spectra of CT DNA incubated with compounds 1−4
(see Supporting Information, Figure S32) at 37 °C and pH =
7.30 in Tris/HCl buﬀer up to molar ratio drug/DNA = 0.5
show no modiﬁcation of the DNA bands with respect to
untreated CT DNA, indicating that drug−DNA interactions, if
existing, do not induce any observable perturbation on the
DNA secondary structure under our experimental conditions
Higher ratios were also tested, although loss of CD signal was
observed due to precipitation of the DNA induced by 1−4,
most likely because of phosphate charge neutralization by the
cationic compounds, which suggests the existence of an
electrostatic attraction. DNA condensation or precipitation by
neutralization of backbone charges has been previously
described for other ionic ruthenium drugs68 and conﬁrmed
by us for compounds 2 and 3 through ICP-MS analysis of metal
content in the DNA precipitate. In this experiment, 500 μM
concentration DNA solutions were treated with 2 equiv of
ruthenium compounds 2 and 3 for 20 h at 37 °C to promote
DNA precipitation. The samples were then centrifuged, and the
resulting pellets were analyzed for DNA and metal concentration (see Experimental Section for more details). Our results
show ruthenium content values of 2.60 ± 0.26 mg Ru/mg
DNA for compound 2 and 2.43 ± 0.18 mg Ru/mg DNA for
compound 3. This high Ru content in DNA precipitate,
especially when compared to similar Ru compounds interacting
with DNA through covalent interactions,24 suggests that the
key factor promoting the precipitation of DNA is the presence
of the ruthenium compound.
Attempts to obtain additional evidence of drug−CT DNA
interactions were made by performing thermal denaturation
experiments but resulted in cyclometalation of compounds 1
and 2 and hydrolysis of 3 at temperatures above 60 °C, as

caspase inhibition prevented death commitment in a very high
percentage of cells because only 22% were AnnexinV+ 24 h
after washing. However, in the case of 3, the percentage of
AnnexinV+ cells 24 h after washing (32%) equaled that of cell
treated with 3 alone for 24 h (28%), suggesting that in this case
caspase inhibition did not prevent irreversible cell damage
leading to cell death. These results suggest that 2 and 3 could
be acting through diﬀerent mechanisms, with 3 causing caspaseindependent premitochondrial damage. These diﬀerences in
the mechanism of 2 and 3 could explain why 3 is less selective
than 2 for tumor cell lines (Table 1).
Ruthenium compounds have been reported to induce p53dependent and -independent cytotoxicity.13,20 To determine
whether the cytotoxicity of the compounds here is p53dependent, we analyzed the levels of p53 in A549 cells, bearing
wt-p53, after a short-term treatment with 2. As shown in Figure
6, treatment with 2 did not induce the stabilization of p53, and

Figure 6. p53 protein levels after short-term incubation of A549 cells
with 2. B-Actin levels were determined in the same membranes as a
total protein loading control.

even at 3 and 6 h we observed a slight decline in p53 levels,
probably due to cell death and protein loss. These results diﬀer
from that reported with other ruthenium organometallic
compounds that induce short-term p53 accumulation.13,20
However, although p53 protein is induced by RM175 in
HCT116 (colon carcinoma)13 or RDC-9 in A172 (glioblastoma) and HCT116,20 genetic inhibition of p53 does not avoid
the cytotoxicity of these compounds, clearly indicating that
other p53-independent mechanisms can be activated by
ruthenium compounds. Moreover, Gaiddon et al. have shown
that a p53−/− cell line (TK6) exhibits the same sensitivity to
RDC-9 than its p53 +/+ parental cell line (NH32). 20
Furthermore, compounds 1−3 showed high toxicity against
p53 mutated cell lines (Jurkat, MiaPaca2, DU-145, and MDAMB-231) as shown in Table 1. Because the activity of cisplatin
has been reported to be p53-dependent, new organometallic
́
compounds that activate
p53-independent pathways could be
useful in the treatment of tumors with alterations in p53, the
most frequently mutated gene in human cancer.
2.3. Reactivity with Biomolecules. 2.3.1. Interactions with
DNA. Because DNA replication is a key event for cell division, it
is among critically important targets in cancer chemotherapy.
Most cytotoxic platinum drugs form strong covalent bonds with
DNA bases.57 However, a variety of platinum compounds act as
DNA intercalators upon coordination to the appropriate
ancillary ligands.58 The more thoroughly studied ruthenium
antitumor agents (Chart 1) have displayed diﬀerences with
respect to their interactions with DNA depending on their
structure.4 Thus, while NAMI-A is known to have fewer and
weaker interactions with DNA than cisplatin,4 indazolium
bisindazoletetrachlororuthenate (KP1019) undergoes interactions similar to cisplatin but with a lower intensity in terms of
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Figure 7. Electrophoresis mobility shift assays for cisplatin, [Ru(η6-p-cymene)Cl]2, and compounds 1−4, 8, and 9 (see Experimental Section for
details). DNA refers to untreated plasmid pBR322. A, B, C, and D correspond to metal/DNAbp ratios of 0.25, 0.5, 1.0, and 2.0, respectively.

and not with the neutral ligands or neutral ruthenium starting
material under the same conditions, which could also be
consistent with charge neutralization or DNA precipitation.
Loss of migration in electrophoresis experiments has been
previously reported as a consequence of DNA precipitation for
other cationic ruthenium compounds.68 The electrophoretic
mobility results also suggest that the electrostatic interaction
between DNA and compounds 1 and 2 is of larger magnitude
than that experienced by 3 and 4 because no mobility
retardation is observed for the latter compounds up to drug/
DNA ratio of 2.0. Further evidence of this could be found in
the fact that lower amount of Ru content in DNA is detected
for compound 3 when compared to compound 2, according to
ICP-MS results.
Thus, we hypothesize that the antitumor properties observed
for compounds 1−4, 8, and 9 are due to non-DNA related
mechanisms/factors, as previously observed for other iminophosphorane complexes described by us44−49 and some other
ruthenium compounds (refs 4, 5, and 8 and refs therein).
2.3.2. Inhibition of Capthesin B. Cathepsin B (cat B) is an
abundant and ubiquitously expressed cysteine peptidase of the
papain family, which has turned out to be a prognostic marker
for several types of cancers.70 Cathepsin B seems to be involved
(along with other cathepsins) in metastasis, angiogenesis, and
tumor progression.71 It has been proposed that cat B may be a
possible therapeutic target for the control of tumor
progression.72 RAPTA Ru compounds which inhibit cat B
with IC50 in the low micromolar range can reduce the mass and
number of metastases in vivo.73 We therefore, studied the
inhibition of Cat B by compound 2 (see Experimental Section
for details). Compound 2 does not inhibit the enzymatic
activity of cat B at concentrations up to 100 μM, indicating that
this protease may not be a target for this type of arene−
ruthenium(II) derivatives.
2.3.3. Interactions with HSA. Human serum albumin (HSA)
is the most abundant carrier protein in plasma and is able to
bind a variety of substrates including metal cations, hormones,
and most therapeutic drugs. It has been demonstrated that the
distribution, the free concentration, and the metabolism of
various drugs can be signiﬁcantly altered as a result of their
binding to the protein.74 HSA possesses three ﬂuorophores,

previously discussed, preventing us from obtaining reliable
information through this technique.
To gain further insights on the nature of the compound−
DNA interactions, gel electrophoresis studies were also
performed with the ruthenium(II) complexes 1−4, 8, and 9
on plasmid (pBR322) DNA (Figure 7).
For these experiments, cisplatin, all uncoordinated ligands,
and the starting dimeric organometallic ruthenium(II) complex
[Ru(η6-p-cymene)Cl]2 were also measured as controls. Plasmid
pBR322 presents two main forms, OC (open circular or
relaxed) and CCC (covalently closed or supercoiled), which
display diﬀerent electrophoretic mobility. Changes in the
electrophoretic mobility of any of the forms upon incubation
of the plasmid with a compound are usually interpreted as
evidence of interaction. Generally, a drug that induces
unwinding of the CCC form will produce a retardation of the
electrophoretic mobility, while coiling of the OC form will
result in increased mobility. Figure 4 shows the eﬀect of
cisplatin and compounds 1−4, 8, and 9 on DNA pBR322 after
incubation at 37 °C for 20 h in Tris/HCl buﬀer up to drug/
DNA ratio 2.0. As previously reported, cisplatin is able to both
increase and decrease the mobility of the OC and the CCC
forms, respectively.69 Interestingly, treatment with increasing
amounts of 1 and 2 induce retardation of the mobility of the
CCC form of plasmid DNA, while the rest of the compounds,
the neutral ligands, and the Ru starting dimer do not seem to
induce any alteration on the mobility of the plasmid.
The results of CD, ICP-MS, and gel electrophoresis taken
together suggest that compounds 1−4 undergo only electrostatic interactions with DNA. This conclusion is supported by
three main facts: (1) results obtained by CD spectroscopy do
not show evidence of CT DNA modiﬁcations of secondary
structure, suggesting that drug−DNA interactions, if any, are of
weak nature, but neither covalent nor intercalation; (2)
precipitation of CT DNA is observed in CD experiments at
high ratios drug/DNA, and it is further conﬁrmed by ICP-MS
analysis of metal content in DNA precipitates, suggesting
backbone charge neutralization; and (3) retardation of the
plasmid DNA electrophoretic mobility is observed also at high
drug/DNA ratios for compounds 1 and 2, but only when
plasmid DNA is incubated with the cationic metal compounds
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Figure 8. (A) Fluorescence titration curve of HSA with compound 4. Arrow indicates the increase of quencher concentration (10−100 mM). (B)
Stern−Volmer plot for HSA ﬂuorescence quenching observed with compounds 1−4, 8, 9, and cisplatin.

coordination iminophosphorane complexes of d8 metals for
which we also reported a concentration dependent ﬂuorescence
quenching.46−49 On the other hand, the Stern−Volmer plot for
complexes 8 and 9 shows a linear relationship, suggesting the
existence of a single quenching mechanism, most likely
dynamic, and a single binding aﬃnity. The Stern−Volmer
constants for complexes 8 and 9 are 1.81 × 104 and 3.85 × 104
M−1, respectively.
In general, higher quenching by the iminophosphorane
complexes was observed compared to that of cisplatin under
the chosen conditions, most likely due to the faster reactivity of
our compounds with HSA, as compared to cisplatin.
3. Eﬀects on Tumor Growth in Vivo with Compound
2. 3.1. Evaluation of the Lethal and Maximum Tolerated
Doses. The lethal and maximum tolerated doses of compound
2 were evaluated in C57/Black6 mice (see Experimental
Section for details). The lethal dose was determined to be 30
mg/kg/day. No biological samples were collected from those
mice. The MTD was determined to be 10 mg/kg/day, at which

namely tryptophan (Trp), tyrosine (Tyr), and phenylalanine
(Phe) residues, with Trp214 being the major contributor to the
intrinsic ﬂuorescence of HSA. This Trp ﬂuorescence is sensitive
to the environment and binding of substrates, as well as
changes in conformation that can result in quenching (either
dynamic or static).
Thus, the ﬂuorescence spectra of HSA in the presence of
increasing amounts of the compounds 1−5, 8, 9, and cisplatin
were recorded in the 300−450 nm range upon excitation of the
tryptophan residue at 295 nm. The compounds caused a
concentration dependent quenching of ﬂuorescence without
changing the emission maximum or the shape of the peak. All
these data indicate an interaction of the compounds with HSA.
The ﬂuorescence data was analyzed by the Stern−Volmer
equation. While a linear Stern−Volmer plot is indicative of a
single quenching mechanism, either dynamic or static, the
positive deviation observed in the plots of F0/F versus [Q] of
compounds 1−4 (Figure 8) suggests the presence of diﬀerent
binding sites in the protein with diﬀerent binding aﬃnities.75 Of
note, a similar behavior was observed in the case of
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the mice showed no visible signs of distress over the 7 days
course of treatment.
Mice lost weight during the trial in a dose dependent manner
where mice treated with 5, 10, or 20 mg/kg/day lost 15%, 19%,
or 37% body weight, respectively, while vehicle treated mice
gained 3% body weight over the 7 days of treatment. Mice
treated with 20 mg/kg/day were euthanized on day 6 of the
trial as they had lost too much body weight and looked in
distress.
Twenty-four h after the last dose, all the mice used in the
MTD study were euthanized and blood plasma, liver, spleen,
and kidneys were collected and used for histological analysis.
Necropsy and histology indicate that mice treated at 20 mg/kg/
day had discolored livers and atrophied spleens; at 10 mg/kg/
day, much less atrophy and minor discoloration was observed,
while in mice treated at 5 mg/kg/day, there was no detectable
liver discoloration and no observable change in spleen size.
We therefore choose the dose of 5 mg/kg/every other day to
conduct the subsequent in vivo trial with compound 2.
3.2. Eﬀects of 2 in MDA-MB-231 Mouse Xenografts.
Twelve female NOD.CB17-Prkdc SCID/J (nonobese diabetic−
severe combined immunodeﬁciency) were selected for the in
vivo trial. The mice were inoculated with MDA-MB-231 cells
(see Experimental Section for details) and treated when the
tumors were palpable (about 5−6 mm diameter). Each six
MDA-MB-231-transplanted animals received compound 2 (5
mg/kg/every other day) or vehicle (0.9% NaCl) intraperitoneally (ip). To palliate the weight loss observed in the
MTD study, all the mice used in this trial were fed a 46% fatadjusted diet (Harlan Teklad, Madison, WI) plus HydroGel
(Harlan Teklad, Madison, WI) and received subcutaneous
injection of 100 μL normal saline on the oﬀ-treatment day.
In the group treated with 2 (see Table 2 and Figure 9), we
observed a signiﬁcant decrease in tumor size (shrinkage) of

Figure 9. Percent of reduction of tumor burden in a cohort of 12
female NOD.CB17-Prkdc scid/J mice inoculated subcutaneously with
5 × 106 MDA-MB-231 cells. The treatment started when tumors were
palpable (5−6 mm diameter). Six mice were treated with compound 2
(pink bars), six were treated with the vehicle 100 μL of normal saline
(0.9% NaCl) (black bars). 2 was administered in the amount of 5 mg/
kg/every other day.

growth of lung metastases in CBA mice bearing the MCa
mammary carcinoma in the absence of a corresponding action
at the site of primary tumor growth.16,17 More recently, a
ruthenium−arene complex with a perﬂuoroalkyl-containing
amine ligand demonstrated a 90% reduction in the tumor
growth in a xenografted ovarian carcinoma tumor (A2780)
grown in a chorioallantoic membrane (CAM) assay of chicken
embryo.19 As stated above, compound 2 is able to decrease
tumor size.
3.3. Pharmacokinetic Study. The pharmacokinetic proﬁle of
compound 2 in the NOD.CB17-Prkdc scid/J mice used for the
in vivo study described above (Figure 10) is summarized in

Table 2. Eﬀects of 2 on the Tumor Growth of MDA-MB-231
Mammary Carcinoma in NOD.CB17-Prkdc scid/J Mice
treatment group

primary tumor (mm3)

controls
compound 2 (5 mg/kg/eoda × 14)

473.47 ± 45.44
59.58 ± 8.66

a

eod = every other day. Tumor measured on day 28, after the 14th
dose.

56% from the starting volume between day 1 and day 28 of
treatment (after a total of 14 doses), while in the control
vehicle treated group, we observed 200% increase in tumor
volume between day 1 and day 28 of treatment. One 2-treated
mouse was removed from the trial because it was not feeding
itself and showed other signs of distress, none of which were
observed in the other mice on trial. We should note that there
was no signiﬁcant weight loss in mice treated with 5 mg/kg/
every other day. Mice treated with 2 gained an average weight
of 2.88%, while untreated mice gained an average of 18.67%
weight (all groups were fed a 46% fat-adjusted diet).
The results clearly indicate that compound 2 is extremely
eﬃcient in vivo because it not only inhibits tumor growth but
also results in the decrease in the size of the tumors by 56%. It
is interesting to compare these results with those obtained with
other arene−ruthenium(II) derivatives. Compound RM175
was reported to have a ﬁnal primary tumor growth inhibition of
30% at a dose of 7.5 mg/kg/day in an in vivo trial for breast
cancer in mice,14 while the compounds RAPTA-C reduced the

Figure 10. Concentration of compound 2 (ruthenium content) in
plasma at various intervals after the ﬁrst dose.

Table 3. Ruthenium content was determined using inductively
coupled plasma−mass spectrometry (ICP-MS). Compound 2
was absorbed quickly into plasma (t1/2 abs = 0.5 h), and the peak
plasma concentration was reached within 2 h of dosing. The
drug was eliminated slowly from the blood compartment with
an elimination half-life (t1/2e) greater than 12 h. This
elimination half-life is similar to that reported for compounds
RAPTA-C,14 NAMI-A,76 and KP1019.10
During determination of total area under the concentration−
time curve (AUC total), only 7% of the AUC was extrapolated
from the last time point, suggesting a high conﬁdence in the
AUC, Vapp, and apparent clearance (CLapp) determination.
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toxic on human renal proximal tubular cell lines. Initial
mechanistic studies indicate that the cell death type for
compound 2 is mainly through canonical or caspase-dependent
apoptosis. In addition, cell death seems not to be dependent on
p53. The interaction of 2 with DNA is weak and electrostatic in
nature. Compound 2 does not inhibit protease cathepsin B in
concentrations of 100 μM or lower. The eﬃcacy of 2 in vivo
has been demostrated on xenografted breast carcinoma MDAMB-231 tumors grown on NOD.CB17-Prkdc scid/J mice. An
impressive tumor reduction (shrinkage) of 56% was observed
after 28 days treatment (14 doses of 5 mg/kg every other day)
with low systemic toxicity. Pharmacokinetic studies showed a
quick absorption of 2 in plasma with an elimination half-life of
12.67 h (similar to that reported for other ruthenium
derivatives). Importantly, 2 accumulated preferentially in the
breast tumor tissues when compared to kidney and liver, which
may explain its high eﬃcacy in vivo. The simple, cheap, and
accessible synthesis of compound 2, its high water-solubility,
and its encouraging preliminary biological activity in vitro and
in vivo makes it therefore a good candidate for further
evaluation as a potential chemotherapeutic agent.

Table 3. Pharmacokinetic Parameters of Compound 2 after
First Injection in NOD.CB17-Prkdc SCID/J Mice
pharmacokinetic parameters

values

Kabs (h −1)
Ke (h −1)
t1/2e (h)
t1/2abs (h)
tmax (h)
Cmax (μg/mL)
AUCtotal (μg·h/mL)
Vapp (mL)
CLapp (mL/h)

1.39
0.055
12.67
0.50
2.00
2.62
54.47
33.57
1.84

Blood concentration, at 6 h after the last dose of compound 2,
was 4.2 ± 1.3 μg/mL, which is higher (P < 0.1) than the Cmax
after the ﬁrst dose. This suggests an accumulation of compound
2 after each dose. While it is hard to make comparisons with
other ruthenium compounds for which a PK analysis has been
performed (e.g., RAPTA-C,16 NAMI-A,76 and KP101910) due
to the diﬀerent structures, oxidation states (see Chart 1), and
the amounts employed in these studies (for example 70 mg
total of 2 in 14 doses of 5 mg/kg/every other day versus a total
of 400 mg or 200 mg for RAPTA-C), there are some
diﬀerences that can be pointed out. The Vd (volume of
distribution) of 2 when compared to that of more structurally
related arene−ruthenium(II) RAPTA-C derivative is smaller,
which may be due to a higher water solubility of 2 or the
possibility that it binds strongly to plasma proteins. Indeed, we
have seen in a qualitative way that compound 2 binds faster to
HSA than cisplatin (section 2.3). Further studies on the
interaction of 2 with plasma proteins are underway.
At the end of the study, ruthenium content in liver, kidney,
and tumor was determined (Figure 11). The level of compound

■

EXPERIMENTAL SECTION

All manipulations involving air-free syntheses were performed using
standard Schlenk-line techniques under a nitrogen atmosphere or a
glovebox MBraun MOD System. Solvents were puriﬁed by use of a
PureSolv puriﬁcation unit from Innovative Technology, Inc.
Compounds [PhCH2Mn(CO)5],79 [(η6-p-cymene)Ru(μ-Cl)Cl]2,52
[Hg(2-C6H4C(O)NPPh3)Cl],53 and IM ligands Ph3PN-CO-2N-C5H4,51 Ph3PN-8-C9H6N,49 [Cp-P(Ph2)N−CH2-2-NC5H4}Fe(Cp)],48 and Ph3PN-CO-2-C6H451 were prepared by reported
methods. The purity of the compounds, based on elemental analysis, is
≥99.5%. In the case that the compound crystallizes with solvent, the
1
H NMR (CDCl3) spectrum is available in the Supporting
Information. Elemental analyses were performed by Atlantic Microlab
Inc. NMR spectra were recorded in a Bruker AV400 (1H NMR at 400
MHz, 13C NMR at 100.6 MHz, 31P NMR at 161.9 MHz). Chemical
shifts (δ) are given in ppm using CDCl3 or DMSO-d6 as solvent,
unless otherwise stated. 1H and 13C chemical shifts were measured
relative to solvent peaks considering TMS = 0 ppm; 31P{1H} was
externally referenced to H3PO4 (85%). Infrared spectra (4000−250
cm−1) were recorded on a Nicolet 6700 FT-IR spectrophotometer
from nujol mulls between polyethylene sheets. Mass spectra
(electrospray ionization, ESI) were performed on an Agilent Analyzer,
a Bruker Analyzer, or a Waters Q-Tof Ultima analyzer. Conductivity
was measured in an OAKTON pH/conductivity meter in CH3CN
solutions (10−3 M). X-ray collection was performed at room
temperature on a Kappa CCD diﬀractometer using graphite
monochromated Mo Kα radiation (λ = 0.71073 Å). Electrophoresis
experiments were carried out in a Bio-Rad Mini subcell GT horizontal
electrophoresis system connected to a Bio-Rad Power Pac 300 power
supply. Photographs of the gels were taken with an Alpha Innotech
FluorChem 8900 camera. Fluorescence intensity measurements were
carried out on a PTI QM-4/206 SE spectroﬂuorometer (PTI,
Birmingham, NJ) with right angle detection of ﬂuorescence using a
1 cm path length quartz cuvette. Circular dichroism spectra were
recorded using a Chirascan CD spectrometer equipped with a
thermostated cuvette holder. The inhibition of capthesin B experiments were performed by Reaction Biology Corporation.
Synthesis. [(η6-p-Cymene)Ru{(Ph3PN-CO-2-N-C5H4)-κ-N,O}Cl](PF6) (1). [(η6-p-Cymene)Ru(μ-Cl)Cl]2 (0.15 g, 0.25 mmol) was
dissolved in MeOH (15 mL), and Ph3PN(CO)(C5H5-2-N) (0.19 g,
0.5 mmol) was added. To the resulting mixture, KPF6 (0.10g, 0.55
mmol) was added. The mixture was stirred for 4 h. The suspension
was then ﬁltered and washed 3 times with Et2O (10 mL). The solution
was then concentrated, and the precipitate was collected by ﬁltration
and dried in vacuo. Yield: 0.36 g (90%). Anal. Calcd for

Figure 11. Compound 2 ruthenium content in tissues at the end of
eﬃcacy study. Data represents mean ± SD N = 3; * indicates P < 0.05.

2 in liver and kidney was less than 5 μg/g tissue weight, while
the tumor concentration was about 40 μg/g. The high level in
tumor suggests enhanced tumor accumulation of compound 2,
which may explain the high eﬃcacy observed for this
compound in the in vivo studies. The preferential accumulation
of some ruthenium complexes in neoplastic masses in
comparison with normal tissue has been reported before by
diﬀerent researchers.77,78

■

CONCLUSIONS
To conclude, we have demostrated the potential of a highly
water-soluble ruthenium−arene−iminophosphorane compound (2) as an anticancer agent. This compound is active
against a number of cisplatin resistant cell lines while being less
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(s, CNP) ppm. Signals due to the quaternary C atoms were not
observed. IR (cm−1): ν 519 (Ru−N), 1268 (NP). Conductivity
(acetone): 125.60 μS/cm (1:1 electrolyte). Solubility: 112.6 mM or 80
mg/mL (H2O).
[(η 6 -p-Cymene)Ru([{Cp-P(Ph 2 )N−CH 2 -2-NC 5 H 4 }Fe(Cp)]-κN,N)Cl]Cl (4). To a solution of [(η6-p-cymene)Ru(μ-Cl)Cl]2 (0.16 g,
0.26 mmol) in CH2Cl2 (10 mL), [{Cp-P(Ph2)N-CH2-2-NC5H4}Fe(Cp)] (0.25 g, 0.52 mmol) in CH2Cl2 (10 mL) was added and
stirred for 40 min. The solvent removed to dryness under reduced
pressure. The solid was dissolved in CH2Cl2, and 25 mL of Et2O were
added. The solid formed was then ﬁltered and dried in vacuo. Yield:
0.30 g (81%). Anal. Calcd for C38H39N2FePCl2Ru·3.5H2O (845.59):
C, 53.98; H, 5.48; N, 3.31. Found: C, 54.02; H, 5.30; N 3.47%. ESIMS: m/z: 747.0 (100%, [M − Cl]+, calcd 747.1), 613.0 (100%, [M-pcymene-Cl], calcd 612.98). 31P {1H} NMR (CDCl3): δ 46.40 (s),
(DMSO-d6): 45.99 (s), (D2O): 46.95 (s). 1H NMR (CDCl3): δ 0.99
(3H, d, J = 5.4 Hz, CH3, η6-p-cymene), 1.23 (3H, m, CH3 + CH2, η6-pcymene, NCH2C), 2.03 (3H, s, CH3, η6-p-cymene), 3.51 (1H, m, CH,
η6-p-cymene), 3.98 (5H, s, C5H5), 4.42−4.78 (6H, m, CH2 + C5H4),
4.79 (2H, m, Cp), 5.17−5.62 (4H, m, CH, η6-p-cymene), 7.45−7.68
(10H, m, Hm + Ho + Hp), 7.83 (1H, d, J = 7.4 Hz, H5, C5H4N), 7.98
(2H, d, J = 7.7 Hz, H3+4, C5H4N), 9.09 (1H, d, J = 4.7 Hz, H6,
C5H4N). 13C{1H} (CDCl3): δ 18.91 (s, CH3, η6-p-cymene), 21.99 (d,
CH3, η6-p-cymene), 23.25 (s, CH3, η6-p-cymene), 31.30 (s, CH, η6-pcymene), 70.55 (s, Cp), 72.24 (d, J = 9.9 Hz, Cp), 73.73 (d, J = 9.9 Hz,
Cp), 75.03 (m, Cp), 83.29 (d, CH, J = 14.4 Hz, η6-p-cymene), 85.98
(d, 2CH, J = 8.3 Hz, η6-p-cymene), 87.09 (s, CH, η6-p-cymene), 99.99
(s, C, η6-p-cymene), 103.8 (s, C, η6-p-cymene), 124.9 (s, Ph), 128.4−
128.8 (m, Ph), 130.2 (s, Cipso), 133.0−133.3 (s, Ph), 133.9−134.0 (d,
C3 + C4, J = 10.1 Hz, C5H4N), 138.8 (s, C4, C5H4N), 155.1 (s, C2,
C5H4N), 164.1 (s, C6) ppm. . IR (cm−1): ν 488 (Ru−N), 1116 (N
P). Conductivity (MeCN): 130.37 μS/cm (1:1 electrolyte). Solubility:
89.5 mM or 70 mg/mL (H2O).
[PTAN-C(O)-2-C6H5] (5). PTA (0.34 g, 2.18 mmol) and
benzamide (0.264 g, 2.18 mmol) were placed in a Schlenk ﬂask
under nitrogen. Dry, degassed THF (10 mL) was added and to this
solution, tBuDAD (N,N-bis(tert-butyl)1,4-diazabutadiene) (0.503g,
2.18 mmol) in dry and degassed THF (4 mL) was added dropwise
at 0 °C. The reaction was left stirring at RT for 2.5 h. After this period,
the solvent was removed to dryness under reduced pressure. The
white residue was washed three times with Et2O (15 mL), giving a
white solid that was ﬁltered and dried in vacuo. Yield: 0.53 g (88%).
Anal. Calcd for C13H17N4OP (276.11): C, 56.52; H, 6.20; N, 20.28.
Found: C, 55.55; H, 6.16; N 20.69%. ESI-MS: m/z: 277.12.0 (99.6%,
[M]+, calcd 276.11). 31P{1H} NMR (CDCl3): δ −30.8 (s). 1H NMR
(CDCl3): δ 4.32−4.63 (12H, m, PTA), 7.38 (2H, t, J = 7.6 Hz, H3 +
H5, C6H5), 7.44 (1H, t, J = 7.1 Hz, H4, C6H5), 8.07 (2H, d, J = 7.5 Hz,
H2 + H6, C6H5). 13C{1H} NMR (CDCl3): δ 55.10 (d, J = 47.2 Hz,
PTA), 72.60 (d, J = 8.9 Hz, PTA), 128.08 (s, C3 + C5, C6H4), 129.21
(s,C2 + C6, C6H4), 131.47 (s, C4), 136.74 (d, J = 17.7 Hz, C1), 179.28
(s, J = 9.6 Hz, CO). Conductivity (acetone): 2.08 μS/cm (neutral).
[(CO)4Mn(2-C6H4C(O)NPTA)] (6). PhCH2Mn(CO)5 (0.43 g, 1.5
mmol) and PTANC(O)Ph (5) (0.41 g, 1.5 mmol) were reﬂuxed in
n-hexane (45 mL) for 4 h. The hot solution was ﬁltered, and the
yellow ﬁltrate reduced in volume until signs of crystallization became
evident. Storage at −20 °C gave yellow crystals of (CO)4Mn(2C 6 H 4 C(O)NPTA). Yield: 0.59 g (90%). Anal. Calcd for
C17H16N4O4PMn (442.02): C, 46.07; H, 3.65; N, 12.67. Found: C,
45.69; H, 3.56; N 12.72%. ESI-MS: m/z: 443.03 (100%, [M], calcd
443.03), 415.04 (100%, [M − CO], calcd 415.04), 386.01 (100%, [M
− 2CO], calcd 387.04), 331.05 (100%, [M − 4CO], calcd 331.05). 31P
{1H} NMR (CDCl3): δ −15.27 (s). 1H NMR (CDCl3): δ 4.32−4.58
(12H, m, PTA), 7.16 (1H, t, J = 7.5, 14.8 Hz, H4, C6H4), 7.38 (1H, t, J
= 7.5, 14.5 Hz, H3, C6H4), 7.68 (1H, d, J = 7.6 Hz, H2, C6H4), 7.93
(1H, d, J = 7.4 Hz, H5, C6H4). 13C{1H} (CDCl3): δ 53.30 (d, J = 43.3
Hz, PTA) ppm. 72.54 (d, J = 9.8 Hz, PTA), 124.02 (s, C4, C6H4),
128.60 (s, C2, C6H4), 132.55 (s, C3, C6H4), 139.93 (s, C1), 141.25 (s,
C5, C6H4), 171.36 (s, CO), 185.71 (s, CO), 213.66 (s, CO),
215.97 (s, CO) ppm. Conductivity (acetone): 1.11 μS/cm
(neutral).

C34H33N2OP2F6ClRu (798.07): C, 51.17; H, 4.17; N, 3.51. Found: C,
50.95; H, 4.20; N 3.56%. ESI-MS: m/z: 653.10 (100%, [M − PF6]+,
calcd 653.11). 31P {1H} NMR (CDCl3): δ 25.72 (s), −148.26 to
−140.19 (septet, PF6), (DMSO-d6): 24.27 (s), −152.87 to −130.98
(septet, PF6). 1H NMR (CDCl3): δ 1.10 (6H, dd, J = 6.9, 18.9 Hz,
CH3, η6-p-cymene), 1.69 (3H, s, CH3, η6-p-cymene), 1.65 (3H, s, CH3,
η6-p-cymene), 2.30 (1H, m, CH, η6-p-cymene), 5.48−5.59 (4H, m,
CH, η6-p-cymene), 7.64−7.78 (16H, m, H5, Hm + Ho + Hp), 8.03 (1H,
d, J = 7.7 Hz, H4, C5H4N), 8.35 (1H, d, J = 7.5 Hz, H3, C5H4N), 9.21
(1H, d, J = 5.3 Hz, H6, C5H4N). 13C{1H} (CDCl3): δ 18.10 (s, CH3,
η6-p-cymene), 21.87 (s, CH3, η6-p-cymene), 22.18 (s, CH3, η6-pcymene), 30.79 (s, CH, η6-p-cymene), 81.00 (s, CH, η6-p-cymene),
82.09 (d, CH, J = 8.3 Hz, η6-p-cymene), 82.41 (s, CH, η6-p-cymene),
83.92 (s, C, η6-p-cymene), 124.5 (s, C2, η6-p-cymene), 125.5 (d, Cipso, J
= 100.4 Hz), 127.7 (s, C3, C5H4N), 129.5 (d, Cm, J = 13.0 Hz), 129.8
(s, C5, C5H4N), 133.2 (d, Co, J = 10.4 Hz), 133.8 (s, Cp), 139.3 (s, C4,
C5H4N), 153.7 (s, C6) ppm. The signal due to C2 (C5H4N) and CO
was not observed. IR (cm−1): ν 524 (Ru−N), 834 (v br, PF6−), 1116
(NP), 1540 (CO). Conductivity (acetone): 125.5 μS/cm (1:1
electrolyte).
[(η6-p-Cymene)Ru{(Ph3PN-CO-2-N-C5H4)-κ-N,O}Cl]Cl (2). [(η6p-Cymene)Ru(μ-Cl)Cl]2 (0.15 g, 0.25 mmol) and Ph3PN(CO)(C5H5-2-N) (0.19 g, 0.5 mmol) were stirred in acetone (20 mL) for 3
h. The brown solution was concentrated and 30 mL of Et2O added
dropwise. The orange solid that formed was collected by ﬁltration and
dried in vacuo. Yield: 0.33 g (94%). Anal. Calcd for
C34H33N2OPCl2Ru·2H2O (724.62): C, 56.36; H, 5.15; N, 3.87.
Found: C, 56.41; H, 4.99; N 3.87%. ESI-MS: m/z: 653.1 (100%, [M −
Cl]+, calcd 653.01), 618.1 (100%, [M − 2Cl]2+, calcd 618.1), 519.0
(100%, [M-p-cymene-Cl]+, calcd 519.0). 31P {1H} NMR (CDCl3): δ
25.18 (s), (DMSO-d6): 28.99 (s). 1H NMR (CDCl3): δ 1.00 (6H, dd,
J = 7.0, 24.8 Hz, CH3, η6-p-cymene), 2.01 (3H, s, CH3, η6-p-cymene),
2.25 (1H, m, CH, η6-p-cymene), 5.51−5.71 (4H, m, CH, η6-pcymene), 7.57 (6H, m, Hm), 7.68 (9H, m, Ho + Hp), 7.87 (1H, d, J =
6.0 Hz, H5, C5H4N), 8.03 (1H, d, J = 7.7 Hz, H4, C5H4N), 8.32 (1H, d,
J = 7.4 Hz, H3, C5H4N), 9.62 (1H, d, J = 5.0 Hz, H6, C5H4N);
13
C{1H} (CDCl3): δ 18.47 (s, CH3, η6-p-cymene), 21.82 (s, CH3, η6-pcymene), 22.39 (s, CH3, η6-p-cymene), 30.75 (s, CH, η6-p-cymene),
81.20 (s, CH, η6-p-cymene), 82.60 (d, CH, J = 8.3 Hz, η6-p-cymene),
83.65 (s, CH, η6-p-cymene), 97.87 (s, C, η6-p-cymene), 102.5 (s, C, η6p-cymene), 125.6 (d, Cipso, J = 101.2 Hz), 127.2 (s, C3, C5H4N), 129.5
(d, Cm, J = 12.8 Hz), 130.3 (s, C5, C5H4N), 133.3 (d, Co, J = 10.2 Hz),
133.9 (s, Cp), 139.0 (s, C4, C5H4N), 151.6 (d, C2, J = 24.0 Hz), 156.3
(s, C6), 176.8 (d, CO, J = 24.14 Hz) ppm. IR (cm−1): ν 527 (Ru−
N), 1114 (NP), 1535 (CO). Conductivity (acetone): 124.20 μS/
cm (1:1 electrolyte). Solubility: 145.3 mM or 100 mg/mL (H2O). pH
(5 × 10−5 M in H2O): 5.76.
[(η6-p-Cymene)Ru{(Ph3PN-8-C9H6N)-κ-N,N}Cl]Cl (3). [(η6- pCymene)Ru(μ-Cl)Cl]2 (0.092 g, 0.15 mmol) was dissolved in
CH2Cl2 (15 mL), and Ph3PN-8-C9H6N (0.12 g, 0.3 mmol) was
added. The mixture was stirred for 3 h. The solution was concentrated
to 2 mL and 20 mL of Et2O added to precipitate an orange solid,
which was ﬁltered and dried in vacuo. Yield: 0.18 g (84%). Anal. Calcd
for C37H35N2PCl2Ru·2.5H2O (755.68): C, 58.81; H, 5.34; N, 3.71.
Found: C, 58.95; H, 4.81; N 3.82%. ESI-MS: m/z: 675.13 (100%, [M
− Cl]+, calcd 675.13), 540.0 (100%, [M-p-cymene-Cl]+, calcd 541.02).
31
P {1H} NMR (CDCl3): δ 37.68 (s), (DMSO-d6): 37.84 (s). 1H
NMR (CDCl3): δ 0.73 (3H, d, J = 6.7 Hz, CH3, η6-p-cymene), 1.01
(3H, d, J = 6.6 Hz, CH3, η6-p-cymene), 1.98 (3H, s, CH3, η6-pcymene), 2.44 (2H, m, CH, η6-p-cymene), 5.43 (2H, s, CH, η6-pcymene), 5.72 (2H, s, CH, η6-p-cymene), 6.40 (1H, d, J = 8.0 Hz, H7,
C9H6N), 6.91 (1H, d, J = 8.1 Hz, H7, C9H6N), 7.15 (1H, d, J = 8.1 Hz,
H7, C9H6N), 7.66 (9H, m, Hm + Hp), 7.68 (1H, s, H3, C9H6N), 8.00
(6H, m, Ho), 8.21 (1H, d, J = 8.4 Hz, H4, C9H6N), 8.21 (1H, s, H2,
C9H6N). 13C{1H} (CDCl3): δ 19.20 (s, CH3, η6-p-cymene), 21.02 (s,
CH3, η6-p-cymene), 22.96 (s, CH3, η6-p-cymene), 31.62 (s, CH, η6-pcymene), 118.4 (s, C5, η6-p-cymene), 121.7 (d, C7, J = 10.3 Hz, η6-pcymene), 124.6 (s, C3, η6-p-cymene), 125.8 (s, C6), 129.4 (s, C8),
129.6 (d, Cm, J = 12.7 Hz), 130.0 (s, Cipso), 134.1 (s, Cp), 134.9 (d, Co,
J = 9.8 Hz), 138.4 (d, C4), 144.7 (s, C9H6N), 144.9 (s, C9H6N), 149.2
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[Hg(2-C6H4C(O)NPTA)Cl] (7). (CO)4Mn(2-C6H4C(O)NPTA)
(6) (0.44 g, 1.0 mmol) and HgCl2 (0.54 g, 2.0 mmol) were reﬂuxed in
methanol (55 mL) for 5 h, during which time the solution turned
yellow and a white solid formed. The mixture was cooled in an ice−
water bath and subsequently ﬁltered. The white solid formed was
washed well with cold methanol. The solid was redissolved in CH2Cl2
(<200 mL) and ﬁltered through Celite. The resulting clear solution
was reduced in volume (<3 mL), and Et2O was added dropwise until
the solution became cloudy. Storage at −20 °C gave white crystals of
7, which were ﬁltered oﬀ, dried, and used without further puriﬁcation.
Yield: 0.33 g (65%). Anal. Calcd for C13H16N4OPClHg·0.5CH2Cl2
(553.78): C, 29.28; H, 3.09; N, 10.112. Found: C, 29.08; H, 3.02; N,
9.75%. ESI-MS: m/z: 513.05 (100%, [M + H]+, calcd 513.05), 535.03
(100%, [M + Na]+, calcd 535.04). 31P {1H} NMR (CDCl3): δ −25.68
(s, 2JHg−P = 27.4 Hz). 1H NMR (CDCl3): δ 4.40 (12H, m, PTA), 7.39
(2H, t, J = 7.6 Hz, H2 + H4, C6H4), 7.51 (1H, t, J = 7.5 Hz, H3, C6H4),
8.23 (1H, d, J = 8.1 Hz, H5, C6H4). 13C{1H} (CDCl3): δ 52.71 (d, J =
45.9 Hz, TPA), 72.76 (d, J = 9.5 Hz, PTA), 128.33 (s, C4, C6H4)
129.84 (s, C5, C6H4), 131.98 (s, C3, C6H4), 136.31 (s, C2, C6H4),
signals corresponding to NCO, C1and C6 were not observable.
Conductivity (acetone): 0.73 μS/cm (neutral) μS/cm.
[(η6-p-Cymene)Ru((Ph3PN-CO-2-C6H4)-κ-C,N)Cl] (8). [Hg(2C6H4C(O)NPPh3)Cl] (0.12 g, 0.2 mmol) and [(η6-p-cymene)Ru(μ-Cl)Cl]2 (0.13 g, 0.22 mmol) were reﬂuxed in MeCN (20 mL) for 7
days, after which a yellow precipitate formed. The pale-yellow solid
was ﬁltered oﬀ and discarded, and the orange solution was
concentrated to dryness. The solid was dissolved in CH2Cl2 and
ﬁltered through Celite. The solvent was removed under reduced
pressure to a minimum, followed by addition of Et2O (∼20 mL). The
orange solid was ﬁltered oﬀ and dried in vacuo. Yield: 0.049 g (37%).
Anal. Calcd for C35H33NOPClRu·2H2O (687.18): C, 61.18; H, 5.43;
N, 2.04. Found: C, 60.97; H, 5.05; N 2.35%. ESI-MS: m/z: 616.13
(100%, [M − Cl]+, calcd 616.13). 31P {1H} NMR (CDCl3): δ 20.63
(s), (DMSO-d6): 21.15 (s). 1H NMR (CDCl3): δ 1.31 (6H, d, J = 6.9
Hz, CH3, η6-p-cymene), 2.18 (3H, s, CH3, η6-p-cymene), 2.95 (1H,
sept, J = 6.9 Hz, CH, η6-p-cymene), 5.37 (2H, d, J = 6.0 Hz, CH, η6-pcymene), 5.49 (2H, d, J = 6.0 Hz, CH, η6-p-cymene), 7.42−7.48 (2H,
m, H3 + H4), 7.49−7.53 (6H, m, Hm), 7.56−7.61 (3H, m, Hp), 7.84−
7.89 (6H, m, Ho), 8.36−8.37 (2H, dd, J = 1.4, 8.0 Hz, H2 + H5).
13
C{1H} (CDCl3): δ 19.02 (s, CH3, η6-p-cymene), 22.21 (s, 2CH3, η6p-cymene), 30.68 (s, CH, η6-p-cymene), 80.58 (s, CH, η6-p-cymene),
81.32 (s, CH, η6-p-cymene), 96.77 (s, C, η6-p-cymene), 101.25 (s, C,
η6-p-cymene), 127.65 (s, C3 + C4), 127.92 (s, C6), 128.62−128.74 (d,
Cm, J = 12.4 Hz), 128.91 (s, Cipso,), 129.51−129.53 (d, J = 3.02 Hz, C2
+ C5), 130.67 (s, C3 + C4), 132.19−132.22 (d, Cp, J = 2.9 Hz),
133.13−133.24 (d, Co, J = 9.6 Hz), 138.51−138.72 (d, J = 20.6 Hz,
C−Ru), 176.26 (s, CO) ppm. IR (cm−1): ν 517 (Ru−N), 1162
(NP), 1593 (CO). Conductivity (acetone): 3.76 (neutral) μS/
cm.
[(η6-p-Cymene)Ru{(PTAN-CO-2-C6H4)-κ-C,N}Cl] (9). [Hg(2C6H4C(O)NPTA)Cl] (6) (0.1 g, 0.2 mmol) and [(η6-p-cymene)Ru(μ-Cl)Cl]2 (0.13 g, 0.2 mmol) were reﬂuxed in CH2Cl2 (20 mL) for
3 days. Subsequently, the solvent was removed to dryness and the
yellow solid obtained was dissolved in CHCl3 and ﬁltered through
Celite. The solvent was removed under reduced pressure to a
minimum, followed by addition of Et2O. The yellow solid obtained
was collected by ﬁltration and dried in vacuo. Yield: 0.14 g (66%).
Anal. Calcd for C23H30N4OPClRu (546.01): C, 50.59; H, 5.54; N,
10.26. Found: C, 50.32; H, 5.20; N 10.53%. ESI-MS: m/z: 546.0
(100%, [M − Cl]+, calcd 546.06), 412.0 (100%, [M − p-cymene]−,
calcd 412.0). 31P {1H} NMR) (CDCl3): δ −16.3 (s), (DMSO-d6):
−11.98 (s). 1H NMR (DMSO-d6): δ 0.61 (3H, d, J = 6.7 Hz, CH3, η6p-cymene), δ 0.99 (3H, d, J = 6.8 Hz, CH3, η6-p-cymene), 2.34 (3H, s,
CH3, η6-p-cymene), 2.24 (1H, sept, J = 7.1 Hz, CH, η6-p-cymene),
4.47−4.67 (12H, m, PTA), 5.81 (2H, d, CH, η6-p-cymene), 6.06 (1H,
d, J = 6.5 Hz, CH, η6-p-cymene), 6.74 (1H, d, J = 6.9 Hz, CH, η6-pcymene), 7.11 (1H, t, J = 7.7 Hz, H4), 7.31 (1H, t, J = 7.5 Hz, H3),
7.37 (1H, d, J = 7.5 Hz, H5), 7.81 (d, 1H, J = 7.5 Hz, H2). 13C{1H}
(DMSO-d6): δ 18.70 (s, CH3, η6-p-cymene), 19.97 (s, CH3, η6-pcymene), 24.13 (s, CH3, η6-p-cymene), 31.00 (s, CH, η6-p-cymene),

51.82 (s, PTA), 52.22 (s, PTA), 71.50 (d, J = 40.5 Hz, PTA), 86.72 (s,
CH, η6-p-cymene), 87.22 (s, CH, η6-p-cymene), 95.97 (s, CH, η6-pcymene), 100.6 (s, C, η6-p-cymene), 127.65 (s, C4), 128.6 (s, C5),
128.6 (s, Cipso,), 132.6 (s, C3), 138.6−138.7 (d, J = 20.6 Hz, C−Ru),
141.1 (s, C2), 183.9 (s, CO) ppm. IR (cm−1): ν 562 (Ru−N), 1314
(NP), 1582 (CO). Conductivity (acetone): 25.4 (neutral) μS/
cm. Solubility: 0.79 mM or 0.43 mg/mL (H2O).
X-ray Crystallography. Single crystals of 1 (see details in Table
S1 in Supporting Information) were mounted on a glass ﬁber in a
random orientation. Data collection was performed at RT on a Kappa
CCD diﬀractometer using graphite monochromated Mo Kα radiation
(λ = 0.71073 Å). Space group assignments were based on systematic
absences, E statistics, and successful reﬁnement of the structures. The
structures were solved by direct methods with the aid of successive
diﬀerence Fourier maps and were reﬁned using the SHELXTL 6.1
software package. All non-hydrogen atoms were reﬁned anisotropically. Hydrogen atoms were assigned to ideal positions and reﬁned
using a riding model. Details of the crystallographic data are given in
Table S1 (Supporting Information). These data can be obtained free
of charge from The Cambridge Crystallographic Data Center via www.
ccdc.cam.ac.uk/data_request/cif. (CCDC 1008354) or in the
Supporting Information. Crystals of 1 (orange prisms with
approximate dimensions 0.26 × 0.24 × 0.21 mm3) were obtained
from a solution of 1 in CH2Cl2 by slow diﬀusion of Et2O at RT.
Cell Culture, Inhibition of Cell Growth, and Cell Death
Analysis. Cell Culture. The human T-cell leukemia Jurkat (clone
E6.1) and the prostate carcinoma DU-145 were routinely cultured in
RPMI 1640 medium supplemented with 5% fetal calf serum (FCS), Lglutamine, and penicillin/streptomycin. A549 (lung carcinoma),
MiaPaca2 (pancreatic carcinoma), MDA-MB-231 (Triple negative
breast carcinoma), and 293T (nontumoral embryonic kidney cells)
were cultured in DMEM medium supplemented with 10% FCS, Lglutamine, and penicillin/streptomycin. Media for A549 cells were also
supplemented with 2.2 g/L Na2CO3, 100 μg/mL pyruvate, and 5 mL
nonessential amino acids (Invitrogen). All these media will be referred
as “complete medium” hereinafter. Cell cultures were maintained in a
humidiﬁed atmosphere of 95% air/5% CO2 at 37 °C.
MTT Toxicity Assays. For toxicity assays cells (5 × 104 for Jurkat
cells and 104 for adherent cell lines) were seeded in ﬂat-bottom 96-well
plates (100 μL/well) in complete medium. Adherent cells were
allowed to attach for 24 h prior to addition of cisplatin or tested
compounds. Compounds were added at diﬀerent concentrations in
triplicate. Cells were incubated with cisplatin or compounds for 24 h,
and then cell proliferation was determined by a modiﬁcation of the
MTT-reduction method. Brieﬂy, 10 μL/well of MTT (5 mg/mL in
PBS) was added, and plates were incubated for 1−3 h at 37 °C.
Finally, formazan crystal was dissolved by adding 100 μL/well iPrOH
(0.05 M HCl) and gently shaking. The optical density was measured at
570 nm using a 96-well multiscanner autoreader (ELISA). In some
experiments, total cell number and cell viability were determined by
the Trypan Blue exclusion test.
Cell Culture and XTT Assay for RPTC Cells. The human renal
proximal tubular cells (RPTC), a nontumoral human kidney epithelial
cell line (obtained from Lifeline Cell Technology, Frederick,
Maryland, USA), were cultured in Lifeline’s RenaLife Medium
containing RenaLife LifeFactors with 2.4 mM L-glutamine, 5 I1̂ /4 g/
mL rh insulin, 1.0 I1̂ /4 M epinephrine, 10 nM triiodothyronine, 0.1 I1̂ /4
g/mL hydrocortisone hemisuccinate, 10 ng/mL rh EGF, 0.5% FBS,
and 5 I1̂ /4 g/m transferrin PS (all from Lifeline Cell Technology), at
37 °C in a humidiﬁed atmosphere of 95% of air and 5% CO2
(University of Hawaii Cancer Center, Honolulu, Hawaii, USA). For
evaluation of cell viability, cells were seeded at a concentration of 5 ×
103 cells/well in 90 μL of Lifeline’s RenaLife complete medium into
tissue culture grade 96-well ﬂat bottom microplates (Thermo Scientiﬁc
BioLite Microwell Plate, Fisher Scientiﬁc, Waltham, Massachusetts,
USA) and grown for 24 h. Solutions of the compounds were prepared
by diluting a freshly prepared stock solution (in H2O) of the
corresponding compound in Lifeline’s RenaLife complete medium.
Afterward, the intermediate dilutions of the compounds were added to
the wells (10 μL) to obtain a ﬁnal concentration ranging from 0.1 to
10007
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200 μM, and the cells were incubated for 24 h. Following 24 h drug
exposure, 50 μL of 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2Htetrazolium-5-carboxanilide (XTT) (Roche Diagnostics, Indianapolis,
Indiana, USA) labeling mixture per well was added to the cells at a
ﬁnal concentration of 0.3 mg/mL and incubated for 4 h at 37 °C in a
humidiﬁed atmosphere of 95% of air and 5% CO2. The optical density
of each well (96-well plates) was quantiﬁed using EnVision multilabel
plate readers (PerkinElmer, Waltham Massachusetts, USA) at 450 nm
wavelength to measure absorbance. The percentage of surviving cells
was calculated from the ratio of absorbance of treated to untreated
cells. The IC50 value was calculated as the concentration reducing the
proliferation of the cells by 50% and is presented as a mean (±SE) of
at least two independent experiments each with triplicates.
Cell Death Analysis. Apoptosis/necrosis hallmarks of cells treated
with compounds 2 and 3 were analyzed by measuring mitochondrial
membrane potential and/or exposure of phosphatidylserine. Cells
were treated with diﬀerent concentrations and at diﬀerent incubation
times as indicated in ﬁgure legends. In some experiments, the general
caspase inhibitor z-VAD-fmk was added at 50 μM 1 h before
compounds. For mitochondrial membrane potential determination,
cells (2.5 × 105 in 200 μL) after treatment with compounds were
incubated at 37 °C for 15 min in ABB (140 mM NaCl, 2.5 mM CaCl2,
10 mM Hepes/NaOH, pH 7,4) containing 60 mM tetramethylrhodamine ethyl ester (TMRE, Molecular Probes). Phosphatidylserine
exposure was quantiﬁed by labeling cells with AnnexinV-PE or
AnnexinV-DY636 (Invitrogen) after treatment with compounds.
AnnexinV was added at a concentration of 0.5 μg/mL, and cells
were incubated at room temperature for 15 min. In all cases, cells were
diluted to 1 mL with ABB to be analyzed by ﬂow cytometry
(FACScan, BD Bioscience, Spain).
Intracellular ROS Quantiﬁcation. Oxidative stress induced by
compounds 2 and 3 was analyzed by intracellular staining with the
ﬂuorescent probe 2-hydroxiethidium (2-HE, Molecular Probes). After
16 h of culture in the presence of compounds 1−3, cells were
incubated with 2 μM 2-HE at 37 °C for 15 min. Red ﬂuorescence
produced by reduction of 2-HE to ethidium was quantiﬁed in a ﬂow
cytometer.
Eﬀect of 2 in the Levels of Proteins of the Bcl-2 Family. Jurkat
cells (5 × 105 cells/mL) were treated with 2 (1 μM) for 6 h. At the
end of incubations, total protein extracts from 2 × 106 cells were
prepared in lysis buﬀer and samples (50 μg/lane) were resolved by
SDS-PAGE and transferred onto nitrocellulose membranes. Then,
levels of some members of the Bcl-2 family of proteins were analyzed
by Western Blot using speciﬁc antibodies: Bcl-XL (Cell Signaling, cat.
no. 2764), Bcl-2 (Abcam, cat. no. AB692), Mcl-1 (Santa Cruz Biotech,
cat. no. SC819), Bim (Calbiochem, cat. no. 202000), Puma (Cell
Signaling, cat. no. 4976), and Noxa (Abcam, cat. no. 114C307). After
incubation with primary antibodies, membranes were incubated with
appropriate secondary antibodies conjugated with HRP. Finally,
membranes were revealed using a chemiluminiscence substrate
(Pierce).
Inhibition of Cathepsin B. Cathepsin B, puriﬁed from human
liver (accession no. P07858) and substrate peptide sequence: Z-FRAMC [AMC = 7-amino-4-methylcoumarin] were dissolved on a
buﬀer, 25 mM MES pH 6, 50 mM NaCl, 0.005% Brij35, 5 mM DTT,
and 1% DMSO, with a ﬁnal concentration of 10 μM. The enzyme
solution was delivered into the reaction well. 2 (1% DMSO solution)
was delivered into the enzyme mixture by acoustic technology
(Echo550; nanoliter range), incubated for 10 min at room temp. The
substrate solution was delivered into the reaction well to initiate the
reaction. The enzyme activity was monitored (Ex/Em = 355/460 nm)
as a time-course measurement of the increase in ﬂuorescence signal
from ﬂuorescently labeled peptide substrate for 120 min at room
temperature. The data was analyzed data by taking slope (signal/time)
of linear portion of measurement. The slope was calculated by using
Excel, and curve ﬁts were performed using Prism software.
Interaction of Compounds 1−4, 8, 9, [(η6-p-Cymene)Ru(μCl)Cl]2, and Cisplatin with Plasmid (pBR322) DNA by Electrophoresis (Mobility Shift Assay). First, 10 μL aliquots of pBR322
plasmid DNA (20 μg/mL) in buﬀer (5 mM Tris/HCl, 50 mM

NaClO4, pH = 7.39) were incubated with diﬀerent concentrations of
the compounds (1−4, 8, 9, [(η6-p-cymene)Ru(μ-Cl)Cl]2) (in the
range 0.25 and 2.0 metal complex:DNAbp) at 37 °C for 20 h in the
dark. Samples of free DNA and cisplatin-DNA were prepared as
controls. After the incubation period, the samples were then loaded
onto the 1% agarose gel. The samples were separated by electrophoresis for 1.5 h at 80 V in Tris-acetate/EDTA buﬀer (TAE).
Afterward, the gel was stained for 30 min with a solution of GelRed
nucleic acid stain.
Interaction of Compounds 1−4 with Calf Thymus DNA by
Circular Dichroism. Stock solutions (5 mM) of each complex were
freshly prepared in water prior to use. The right volume of those
solutions was added to 3 mL samples of an also freshly prepared
solution of CT DNA (48 μM) in Tris/HCl buﬀer (5 mM Tris/HCl,
50 mM NaClO4, pH = 7.39) to achieve molar ratios of 0.1, 0.25, 0.5,
1.0, and 2.0 drug/DNA. The samples were incubated at 37 °C for a
period of 20 h. All CD spectra of DNA and of the DNA−drug adducts
were recorded at 25 °C over a range 220−420 nm and ﬁnally corrected
with a blank and noise reduction. The ﬁnal data is expressed in molar
ellipticity (millidegrees).
DNA Precipitation with Compounds 2 and 3 and
Quantiﬁcation of Ruthenium by ICP-MS. Stock solutions of
compounds 2 and 3 (4 mM in water) and CT DNA (11.56 mM in 5
mM Tris/HCl, 50 mM NaClO4, pH = 7.39) were freshly prepared
prior to use. Then 216 μL of DNA stock solution were diluted in 3.53
mL of buﬀer and 1.25 mL of compound stock solution were then
added to achieve 5 mL ﬁnal volume at concentrations of 500 μM in
DNA and 1 mM in metal compound. Each sample was incubated at 37
°C for a period of 20 h, then cooled down to room temperature and
centrifuged at 3000 rpm for 15 min and at 4000 rpm for extra 40 min.
The supernatant was separated and analyzed for CT DNA
concentration by CD spectroscopy. The resulting pellet was washed
twice with ice-cold ethanol (1 mL), centrifuged at RT for 1 min at
4000 rpm, dried under high vacuum, and analyzed for Ru content by
ICP-MS. The total amount of DNA in each sample was 0.92 mg. Every
experiment was run in duplicate.
Interaction of Compounds 1−4, 8, 9, and Cisplatin with HSA
by Fluorescence Spectroscopy. A solution of each compound (8
mM) in DMSO was prepared, and 10 aliquots of 2.5 μL were added
successively to a solution of HSA (10 μM) in phosphate buﬀer (pH =
7.4) to achieve ﬁnal metal complex concentrations in the range 10−
100 μM. The excitation wavelength was set to 295 nm, and the
emission spectra of HSA samples were recorded at room temperature
in the range of 300 to 450 nm. The ﬂuorescence intensities of all the
metal compounds, the buﬀer, and the DMSO are negligible under
these conditions. The ﬂuorescence was measured 240 s after each
addition of compound solution. The data were analyzed using the
classical Stern−Volmer equation F0/F = 1 + KSV[Q].
In Vivo Tests. All animal experiments were performed according to
the University of Hawaii Cancer Center regulations and by approval of
the responsible authorities (UH IACUC number: A3423−01).
Determination of Lethal Dose (LD) and Maximum Tolerated
Dose (MTD) of 2 in Mice. Fourteen female C57/Black 6 mice from
Jackson Laboratory (Bar Harbor, ME, and Sacramento, CA, USA),
ages 8−14 weeks and weighing 18−26 g, were used for these
experiments. Mice were randomized to treatment groups based on
their age to ensure equivalent distribution between the groups. At trial
end-point, the mice were sacriﬁced and liver, spleen, kidney, and blood
plasma were collected and then processed for further analysis. Gross
and microscopic evaluations of liver, spleen, and kidney were
conducted. The weight of 2 treated mice compared and that of
vehicle-treated mice as measured twice weekly.
The lethal dose (LD) was determined by injecting once mouse ip
once 5, 10, 20, 30, or 50 mg/kg/day and one vehicle control with 100
μL of normal saline (0.9% NaCl)). The dose that killed the mice
within 24 h was set to be lethal dose. The lethal dose was conﬁrmed by
administering that dose to a second mouse. The maximum tolerated
dose (MTD) was determined by injecting two mice with 5, 10, or 20
mg/kg/day over 6 days or 20 mg/kg/every other day over 6 days and
one vehicle control mouse with 100 μL of normal saline (0.9% NaCl).
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The MTD was conﬁrmed by administering the determined dose to 3
mice over 7 days and three vehicle control mice with 100 μL of normal
saline (0.9% NaCl).
Study of the Eﬀects of 2 in MDA-MB-231 Xenografts in
Mice. First, 12 female NOD.CB17-Prkdc scid/J (nonobese diabetic−
severe combined immunodeﬁciency) mice from Jackson Laboratory
(Bar Harbor, ME and Sacramento, CA, USA) for the xenograft
experiment (ages 8−12 weeks and weighing 19−24 g) were used. Each
mouse received 5 × 106 tumor cells subcutaneously without anesthesia.
Exponentially growing estrogen-receptor α-negative MDA-MB-231
human breast cancer cells were then suspended in 1:1 ratio 50 μL of
phosphate-buﬀered saline (PBS; pH 7.4) plus 50 μL of matrigel (BD
Biosciences, San Jose, CA, USA) were injected subcutaneously on both
left and right ﬂank of each mouse. The diameter of the tumors was
measured once weekly using an electronic digital caliper, and the
tumor volume (TV) was calculated according to the empirical
equation TV = (a)(b2) × π/6, where a = longest dimension and b =
largest dimension orthogonal to a. The median volumes of each group
were normalized to the initial tumor volume, resulting in the relative
tumor volume. Each six MDA-MB-231-transplanted animals received
compound 2 (5 mg/kg/every other day) or vehicle (0.9% NaCl)
intraperitoneally (ip). Treatment started when tumors were palpable
(about 5−6 mm diameter). To palliate the weight loss observed in the
MTD study, the mice were fed a 46% fat-adjusted diet (Harlan Teklad,
Madison, WI) plus HydroGel (Harlan Teklad, Madison, WI) and
received subcutaneous injection of 100 μL of normal saline (0.9%
NaCl) to improve hydration. Mice were randomized to treatment
groups based on their starting tumor burden at 12 weeks of age to
ensure equivalent distribution between the two groups. At trial endpoint, the mice were sacriﬁced and tumors measured again after
excision and then processed for further analysis. Histological as well as
biochemical evaluations of blood, liver, intestine, kidney, and lung
were conducted. Tumor volumes were graphed for (2) treated mice
compared to vehicle-treated mice based on weekly external digital
caliper measurements.
Pharmacokinetic Study: Determination of Ruthenium
Content in the Organs, Entire Blood, and Plasma. Female
NOD.CB17-Prkdc scid/J nice bearing subcutaneous MDA-MB-231
tumors and treated with compound 2 (5 mg/kg/every other day)
intraperitoneally were used for pharmacokinetic evaluation of the drug
in blood and other tissues. Blood was collected retroorbitally using a
heparin coated glass capillary into heparinized blood collection vials on
ice at time intervals of 30 min, 2 h, 6 h, 24 h,and 48 h after the ﬁrst
dose. The blood samples were centrifuged at 2800 rpm at 4 °C for 15
min, and the supernatant plasma was transferred into 1.5 mL
microcentrifuge tubes and maintained at −80 °C until analysis.
Ruthenium content was determined using inductively coupled
plasma−mass spectrometry (ICP-MS). First, 50 μL of plasma was
transferred into a glass vial, and 1 mL of concentrated acid mix
(comprising of 75% of 16 N nitric acid and 25% of 12 N hydrochloric
acid) was added. The mixture was then heated at 90 °C for 5 h. After
cooling, the samples were diluted with water, and 40 ppb of indium
internal standard was added and analyzed in a Thermo Scientiﬁc
XSERIES 2 ICP-MS with ESI PC3 Peltier cooled spray chamber with
SC-FAST injection loop and SC-4 autosampler. All the elements were
analyzed using He/H2 collision-reaction mode. Plasma from control
mice was spiked with the test compound to determine the extraction
eﬃciency.
At the end of the study, liver, kidney, and tumor of the animals were
harvested, weighed, and transferred into glass vials. One mL of water
was added to each sample and subjected to ultrasonic tissue disruption
at 15 W power for 1 min. The tissue homogenates were frozen at −80
°C for 2 h and lyophilized. The lyophilized product was heated at 90
°C with the concentrated acid mix (described above) for 5 h, cooled,
diluted with water, and analyzed for ruthenium by ICP-MS.
Pharmacokinetic estimates were obtained from the plasma concentration−time proﬁles by noncompartmental analysis using Phoenix
WinNonlin 6.1 (Mountain View, California).
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